Cantabio Pharmaceuticals, Inc.
Other OTCTotal Valuation
Cantabio Pharmaceuticals, Inc. carries a market capitalization of 22,769.00, placing it among publicly traded companies globally.
| Market Cap | 22,769.00 |
| Enterprise Value | N/A |
Share Statistics
Cantabio Pharmaceuticals, Inc. currently has 19,320.00 shares outstanding.
| Shares Outstanding | 19,320.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.12 |
| P/TBV Ratio | -0.30 |
| P/FCF Ratio | -0.71 |
| P/OCF Ratio | -0.71 |
Financial Position
Cantabio Pharmaceuticals, Inc. maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.15 |
| Quick Ratio | 0.13 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.10 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -875.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -48.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cantabio Pharmaceuticals, Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 1.01, while the 200-day moving average is 1.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.01 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.33M, while operating income came in at -1.33M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.33M |
| Pretax Income | -1.54M |
| Net Income | -1.54M |
| EBITDA | -1.33M |
| EBIT | -1.33M |
| Earnings Per Share (EPS) | -116.42 |
Balance Sheet
Total book value stands at -4.72M, with working capital of -1.89M providing operational flexibility.
| Cash & Cash Equivalents | 283,371.00 |
| Total Debt | N/A |
| Net Debt | 1.13M |
| Equity (Book Value) | -4.72M |
| Book Value Per Share | -355.77 |
| Working Capital | -1.89M |
Cash Flow
Cantabio Pharmaceuticals, Inc. produced -798,403.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -798,403.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -798,403.00 |
| FCF Per Share | -60.23 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -187.28 |
| FCF Yield | -141.73 |
Stock Splits
Cantabio Pharmaceuticals, Inc.'s most recent stock split took place on August 19, 2021 with a 5000:1 split ratio.
| Last Split Date | 8/19/2021 |
| Split Ratio | 5000:1 |
Scores
Cantabio Pharmaceuticals, Inc. posts an Altman Z-Score of -40.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -40.93 |